Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adefovir dipivoxil for the treatment of chronic hepatitis B

Adefovir dipivoxil treatment results in significant histologic, virologic, and biochemical improvement in patients with chronic hepatitis B, find researchers in the latest issue of the New England Journal of Medicine.

News image

fiogf49gjkf04

Adefovir dipivoxil, a nucleotide analogue, has shown significant antiviral activity in patients with chronic hepatitis B, in phase 1 and 2 clinical trials.

In this double-blind study, a team of international researchers assessed 185 patients with chronic hepatitis B, who were negative for hepatitis B e antigen (HBeAg).

The team randomized patients to receive either 10 mg of adefovir dipivoxil or placebo once daily for 48 weeks.

The team considered that the primary end point to be histologic improvement.

At week 48, 64% of patients who had base-line liver-biopsy specimens available in the adefovir dipivoxil group had improvement in histologic liver abnormalities. This compared with 33% of patients in the placebo group.

The researchers found reductions in serum hepatitis B virus (HBV) DNA levels in the adefovir dipivoxil group. HBV DNA levels fell to less than 400 copies per ml in 51% of patients in the adefovir dipivoxil group, but in none of those in the placebo group.

They determined that the median decrease in log-transformed HBV DNA levels was greater in the adefovir dipivoxil group, than in the placebo (3.91 versus 1.35 log copies per ml).

In addition, the team found that alanine aminotransferase levels had normalized at week 48 in 72% of patients receiving adefovir dipivoxil, compared with 29% those receiving placebo.

No HBV polymerase mutations associated with resistance to adefovir were identified.

Furthermore, the safety profile of adefovir dipivoxil was similar to that of the placebo.

Dr Stephanos Hadziyannis's team concluded, "In patients with HBeAg-negative chronic hepatitis B, 48 weeks of adefovir dipivoxil treatment resulted in significant histologic, virologic, and biochemical improvement, with an adverse-event profile similar to that of placebo".

"There was no evidence of the emergence of adefovir-resistant HBV polymerase mutations."

In a related study in the same publication, a second team of researchers assessed patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg).

In this study, the research team randomly assigned 515 patients to receive 10 mg of adefovir dipivoxil, 30 mg of adefovir dipivoxil, or placebo daily for 48 weeks.

The primary end point of the study was histologic improvement in the 10-mg group.

Patients showing histologic improvement:
- 10 mg adefovir = 53%
- 30 mg adefovir = 59%
- placebo = 25%
New England Journal of Medicine

After 48 weeks of treatment, more patients who received 10 mg or 30 mg of adefovir dipivoxil, than who received placebo, had histologic improvement (53%, 59%, 25%, respectively).

In addition, patients in the adefovir dipvoxil group had a reduction in serum HBV DNA levels, undetectable levels (fewer than 400 copies per ml of serum HBV DNA, normalization of alanine aminotransferase levels, and HBeAg seroconversion.

Again, no adefovir-associated resistance mutations were identified in the HBV DNA polymerase gene.

The research team determined that the safety profile of the 10-mg dose of adefovir dipivoxil was similar to that of placebo.

However, in the 30mg group there was a higher frequency of adverse events and renal laboratory abnormalities.

Dr Patrick Marcellin's team concluded, "In patients with HBeAg-positive chronic hepatitis B, 48 weeks of 10 mg or 30 mg of adefovir dipivoxil per day resulted in histologic liver improvement, reduced serum HBV DNA and alanine aminotransferase levels, and increased the rates of HBeAg seroconversion".

"The 10-mg dose has a favorable risk-benefit profile for long-term treatment".

"No adefovir-associated resistance mutations were identified in the HBV DNA polymerase gene".

New Engl J Med 2003; 348(9): 800-7, 808-16
03 March 2003

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us